Cargando…

2379. It’s Getting Complicated: Outcomes of Clostridiodes difficile PCR Positive/Toxin-Negative Patients

BACKGROUND: The addition of toxin enzyme immunoassay to molecular tests creates challenges in the diagnosis and management of Clostridiodes difficile infection (CDI). In limited samples of PCR+/ toxin- patients, CDI-attributable complications are thought to be rare, even nonexistent. We aimed to cha...

Descripción completa

Detalles Bibliográficos
Autores principales:	Morillas, Jose A, Miller, Ryan, Brizendine, Kyle D, Fraser, Thomas G
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2019
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6809975/ http://dx.doi.org/10.1093/ofid/ofz360.2057

Ejemplares similares

2364. Surprising Prescribing: Treatment Practices following Addition of Toxin Testing to an Existing Molecular Test for Clostridioides difficile
por: Miller, Ryan, et al.
Publicado: (2019)

2359. Prospective Feasibility Study for Novel Ultrasensitive Multiplexed Immunoassay for Clostridiodes difficile Toxins A and B
por: Watson, Lauren, et al.
Publicado: (2019)

972. Asymptomatic Carriage of Clostridiodes difficile and Risk of Subsequent Infection
por: Espiritu, Katrina, et al.
Publicado: (2018)

779. Clostridiodes difficile: Is it time for surveillance! Cost-benefit analysis
por: Yassin, Mohamed, et al.
Publicado: (2020)

A Predictive Model to Identify Complicated Clostridiodes difficile Infection
por: Berinstein, Jeffrey A, et al.
Publicado: (2023)

2373. Impact of a Change in Testing Strategy for Clostridioides difficile Infection on a Publicly Reported Metric and Treatment Days of Therapy
por: Miller, Ryan, et al.
Publicado: (2019)

2393. Dimensions of Cumulative Antibiotic Exposure and Risk of Hospital Onset Clostridiodes Difficile
por: Song, Jiyoun, et al.
Publicado: (2019)

708. Three Stages of Laboratory Stewardship in Improving Appropriate Clostridiodes Difficile Testing
por: Beckman, Shannon, et al.
Publicado: (2023)

2379. Multicenter Evaluation of Ceftazidime–Avibactam for Multidrug-Resistant Gram-Negative Bacterial Infections
por: Jorgensen, Sarah, et al.
Publicado: (2018)

839. Effect of Clostridioides difficile (C. difficile) Toxin Test Reporting on Clinical Treatment and Outcomes of Toxin-Negative PCR-Positive Patients at Five California Hospitals
por: Polage, Christopher R, et al.
Publicado: (2019)

2346. Cost Savings Associated with Implementation of Clinical Decision Support for Clostridiodes difficile Testing
por: Hoegg, Cindy L, et al.
Publicado: (2019)

670. Clinical Characteristics and Outcomes in Patients with Healthcare Facility-Onset Clostridiodes difficile Infections
por: Joshi, Seema, et al.
Publicado: (2023)

753. Impact of COVID-19 on Healthcare Facility-Onset Clostridiodes difficile Infection
por: Suleyman, Geehan, et al.
Publicado: (2021)

749. A Nurse-Driven Protocol for Early Detection of Clostridiodes difficile Infections
por: Beckman, Shannon, et al.
Publicado: (2021)

2424. Shedding of Viable Clostridiodes difficile in Patients Admitted to a Medical Intensive Care Unit
por: Young, Vincent B, et al.
Publicado: (2019)

677. To Treat or Not To Treat: Patients with Clostridioides difficile PCR-positive/Toxin EIA negative Test Results
por: Yang, Krista, et al.
Publicado: (2023)

798. Metronidazole Exposure Prior to Clostridiodes difficile Infection (CDI) is a Risk Factor for Severe C. difficile Disease in Cancer Patients
por: Francisco, Denise Marie A, et al.
Publicado: (2020)

Updates and Opinions in Diagnosis and Treatment of Clostridiodes difficile in Pediatrics
por: Malhotra, Sanchi, et al.
Publicado: (2021)

386. Clostridioides difficile PCR Cycle Threshold to Determine Toxin Positivity Status
por: Crone, Andrew S, et al.
Publicado: (2022)

675. The Fidaxomicin Cascade: Analysis of Success Rates and Barriers of Fidaxomicin Discharge Prescriptions for Inpatients Diagnosed with Clostridiodes Difficile
por: Cook, Ellen, et al.
Publicado: (2023)

706. Effect of the Covid-19 Pandemic on Rates of Recurrent Clostridiodes difficile Infection in the Veterans Affairs System
por: Drekonja, Dimitri M, et al.
Publicado: (2021)

Clinical Correlation of a Clostridium difficile Testing Algorithm Reflexing PCR Positive Specimens to Toxin Enzyme Immunoassay (EIA)
por: Rios, Maria Bueno, et al.
Publicado: (2017)

397. Oral Vancomycin Versus Fidaxomicin for Clostridiodes difficile: A Comparative Retrospective Evaluation across a Large, Multi-center Healthcare System
por: Roemer, Kaleb, et al.
Publicado: (2022)

Risk for Clostridiodes difficile Infection among Older Adults with Cancer
por: Kamboj, Mini, et al.
Publicado: (2019)

2384. The Relationship Between Rifaxamin Use and the Prevalence of Clostridiodes difficile and Vancomycin-Resistant Enterococcus in Patients with Advanced Liver Disease
por: Alberto. De Jesus, Francisco, et al.
Publicado: (2019)

Descriptive Study of Gut Microbiota in Infected and Colonized Subjects by Clostridiodes difficile
por: Sánchez-Pellicer, Pedro, et al.
Publicado: (2021)

747. Association of Clostridiodes difficile Infection Incidence With Renewed Vigor in Infection Prevention Practices With the Onset of the COVID-19 Pandemic
por: Khan, Ahmed A, et al.
Publicado: (2021)

1092. Tuning Down Clostridioides difficile PCR Sensitivity Reduces Treatment for C. difficile Infection in Toxin-Negative Patients With No Increase in Adverse Outcomes
por: Hitchcock, Matthew, et al.
Publicado: (2018)

2379. An Urban Detroit Clinic’s Experience in Bivalent COVID-19 Booster Uptake in People Living with HIV
por: Ramakrishna, Jahanavi M, et al.
Publicado: (2023)

2366. PCR Followed by Toxin EIA for the Diagnosis of C. difficile Infection
por: Zhang, Yu, et al.
Publicado: (2019)

Evidence of within-facility patient–patient Clostridiodes difficile infection spread across diverse settings
por: Justice, Samuel, et al.
Publicado: (2022)

Management and characteristics of patients suffering from Clostridiodes difficile infection in primary care
por: Klezovich-Bénard, Maria, et al.
Publicado: (2021)

The Novel DNA Binding Mechanism of Ridinilazole, a Precision Clostridiodes difficile Antibiotic
por: Mason, Clive S., et al.
Publicado: (2023)

2401. Epidemiology of Clostridium difficile Infection in Intestinal and Multivisceral Transplant Patients at a Single Transplant Center
por: Modi, Anita R, et al.
Publicado: (2019)

Engineered Secretory Immunoglobulin A provides insights on antibody-based effector mechanisms targeting Clostridiodes difficile
por: Bharathkar, Sonya Kumar, et al.
Publicado: (2023)

Identification of ADS024, a newly characterized strain of Bacillus velezensis with direct Clostridiodes difficile killing and toxin degradation bio-activities
por: O’Donnell, Michelle M., et al.
Publicado: (2022)

699. Clinical Outcomes and Management of NAAT-Positive/Toxin-Negative Clostridium difficile Infection: A Systematic Review and Meta-Analysis
por: Prosty, Connor, et al.
Publicado: (2023)

Clinical Characteristics and Outcomes of Hematologic Malignancy Patients with Clostridium difficile Toxin EIA vs. PCR Positive Test Results
por: Ziegler, Matthew, et al.
Publicado: (2017)

Two Groups of Cocirculating, Epidemic Clostridiodes difficile Strains Microdiversify through Different Mechanisms
por: Murillo, Tatiana, et al.
Publicado: (2018)

Clostridiodes difficile in COVID-19 Patients, Detroit, Michigan, USA, March–April 2020
por: Lakkasani, Saraswathi, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_vqgukeqpe92s31n9hvrdngit3r